Tigen Pharmaceuticals

Lexington, KY 40506

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $737K
First Award Date 05/06/98
Most Recent Award Date 06/25/03

Key Personnel

Last Name Name Awards Contact
Burke Thomas G Burke 4
Perez-Soler Roman Perez-Soler 1

5 Awards Won

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 06/25/03 - 08/31/04

DESCRIPTION (provided by applicant): Based on the extensive data generated during the phase I portion of our studies, there is sufficient and compelling information to support the further development of the highly lipophilic and blood-stable topoisomerase inhibitor, DB-67. In part, the pre-clinical and clinica...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/28/01 - 12/31/02

DESCRIPTION (provided by applicant): Based on the extensive data generated during the phase I portion of our studies, there is sufficient and compelling information to support the further development of the highly lipophilic and blood-stable topoisomerase inhibitor, DB-67. In part, the pre-clinical and clinica...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/01 - 03/31/02

DESCRIPTION (PROVIDED BY APPLICANT): DB-67 is a promising new silatecan (silylcamptothecin) analog that displays superior blood stability relative to the FDA-approved camptothecin congeners, topotecan and CPT- 11. DB-67 also exhibits a high degree of anti-cancer potency both in vitro and in vivo. DB-67 is a highly ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 01/05/00 - 06/30/01

DESCRIPTION (Adapted from the application): Combinatorial synthetic methods will serve as the basis for developing novel silane-containing camptothecins (silatecans) and related camptothecins with optimized biological performance. The applicant will combine the power of parallel synthesis with recent innovat...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 05/06/98 - 04/30/00

DESCRIPTION: Topoisomerase inhibition (Ti) is an area of emerging prominence in the chemotherapy of cancer. Tigen Pharmaceuticals in collaboration with Dr. Giovanella of the Stehlin Foundation for Cancer Research now plan to explore the commercial development of novel camptothecin-class topo...